Study finds almost 1 in 3 large clinical trials still not published 5 years after completion
Almost one in three (29%) large clinical trials remain unpublished five years after completion. And of these, 78% have no results publicly available, finds a study published on bmj.com today.
This means that an estimated 250,000 people have been exposed to the risks of trial participation without the societal benefits that accompany the dissemination of their results, say the authors.
They argue that this “violates an ethical obligation that investigators have towards study participants” and call for additional safeguards “to ensure timely public dissemination of trial data.”
Randomized clinical trials are a critical means of advancing medical knowledge. They depend on the willingness of people to expose themselves to risks, but the ethical justification for these risks is that society will eventually benefit from the knowledge gained from the trial.
But when trial data remain unpublished, the societal benefit that may have motivated someone to enrol in a study remains unrealized.
US law requires that many trials involving human participants be registered – and their results posted – on the largest clinical trial website ClinicalTrials.gov. But evidence suggests that this legislation has been largely ignored.
So a team of US-based researchers set out to estimate the frequency of non-publication of trial results and, among unpublished studies, the frequency with which results are unavailable in the ClinicalTrials.gov database.
They searched scientific literature databases and identified 585 trials with at least 500 participants that were registered with ClinicalTrials.gov and completed prior to January 2009. The average time between study completion and the final literature search (November 2012) was 60 months for unpublished trials.
Registry entries for unpublished trials were then reviewed to determine whether results for these studies were available in the ClinicalTrials.gov results database.
Of 585 registered trials, 171 (29%) remained unpublished. Of these, 133 (78%) had no results available in ClinicalTrials.gov. Non-publication was more common among trials that received industry funding (32%) than those that did not (18%).
“Our results add to existing work by showing that non-publication is an important problem even among large randomized trials,” say the authors. Furthermore, the sponsors and investigators of these unpublished trials infrequently utilize the ClinicalTrials.gov results database.
Go deeper with Bing News on:
Clinical trials
- RAPT terminates Phase II trials for lead candidate following clinical hold
RAPT is closing two Phase II trials for Rapt’s lead candidate, zelnecirnon, three months after the FDA placed a clinical hold on them.
- Why We Need More Black Women in Clinical Trials
Black Women remain underrepresented in clinical trials despite efforts of inclusion. Here's how that can change.
- Revolutionary mRNA Cancer Vaccine Shows Immense Promise in First-Ever Human Clinical Trial
In a first-ever human clinical trial of four adult patients, an mRNA cancer vaccine created at the University of Florida rapidly reprogrammed the immune system to target glioblastoma, the deadliest ...
- Buy Rating Reaffirmed for IN8bio Amid Promising Clinical Trials and Strong Pipeline
Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on IN8bio (INAB – Research Report), reducing the price target ...
- Clinical trials aren’t the only way to get involved in sickle cell research
Although columnist Mary Shaniqua is hesitant to join clinical trials, she's found another way to contribute to sickle cell research.
Go deeper with Google Headlines on:
Clinical trials
[google_news title=”” keyword=”clinical trials” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Unpublished trial data
- More children gain hearing as gene therapy for profound deafness advances
Enlarge / Opal Sandy (center), who was born completely deaf because of a rare genetic condition, can now hear unaided for the first time after receiving gene therapy at 11-months-old. She is shown ...
- Controversy Over Suicide Risk in Children and Adolescents Taking Antidepressants: Lessons Learned
In the analysis by Whittington and coauthors, [1] results of 2 published trials suggested that fluoxetine had a favorable risk-benefit profile, and unpublished data supported this finding.
- Therapeutics update: the new era of drug treatments for obesity
Dr Simon Cork, senior lecturer in physiology at Anglia Ruskin University, reviews the latest advances in drug treatment for obesity, including liraglutide, semaglutide and tirzepatide ...
- New Manuscripts
Numbered references to personal communications, unpublished data, or manuscripts either ... if necessary, footnotes. Trial Protocol and Statistical Analysis Plan (SAP) If needed, a protocol ...
- RVPH: Full Year 2023 Results
RVPH READ THE FULL RVPH RESEARCH REPORT 2023 Financial and Operational Results On April 15th, 2024, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported full-year 2023 financial and operational ...
Go deeper with Google Headlines on:
Unpublished trial data
[google_news title=”” keyword=”Unpublished trial data” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]